Date: 2016-10-13
Type of information: Pipeline acquisition
Acquired company: animal health vaccines and pharmaceuticals from Merial portfolio
Acquiring company: Ceva Santé Animale (France)
Amount: undisclosed
Terms: * On October 13, 2016, Boehringer Ingelheim, Merial and Ceva Santé Animale announced that Boehringer Ingelheim and Ceva, a leading global animal health company headquartered in Libourne, France, with vaccine manufacturing presence within the European Union, have entered into a binding put option agreement according to which Ceva will purchase certain assets of Merial’s portfolio in the context of Boehringer Ingelheim’s business swap with Sanofi. Through this step, which follows a thorough evaluation and extensive discussions with the European Commission, Boehringer Ingelheim aims to facilitate the approval process for Boehringer Ingelheim’s acquisition of Sanofi’s animal health business, Merial, by proactively offering up this divestiture to Ceva. The overall transaction, as well as the agreement announced, remain subject to approval by the European Commission and regulatory authorities in different territories. In June 2016, Boehringer Ingelheim and Sanofi signed definitive agreements to swap businesses. The proposed transaction will consist of an exchange of Sanofi’s animal health business Merial and Boehringer Ingelheim’s consumer healthcare business. In order to complete the proposed swap transaction, the approval of regulatory authorities in different territories needs to be obtained. This includes the approval of the European Commission. After approving the consumer healthcare part of the transaction, the European Commission is currently reviewing the animal health transaction. Closing of the BI/Sanofi swap transaction is expected by year-end 2016, upon receipt of all required regulatory approvals.
Details: The global veterinary health company Ceva Santé Animale is focused on the research, development, production and marketing of pharmaceutical products and vaccines for companion animals, livestock, swine and poultry. Its headquarters are in Libourne, France. The company will acquire certain animal health vaccines and pharmaceuticals from the Merial portfolio for swine, bovine and companion animals as well as related intellectual property, manufacturing processes and R&D activities. The package contains the following brands: Circovac (excluding US), Progressis, Mucosiffa, Parvovax, Parvoruvax, Equioxx (excluding US), Genixine, Ketofen® 1% injection and tablets (excluding Canada) and Ketofen® 10% injection (excluding Canada)]. The divestiture does not include the transfer of a manufacturing site, but will be implemented by means of a transfer of all relevant assets.
Related: Veterinary medicine
